Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 12:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 533 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antiretroviral drugs Clear all
Not listed Not applicable Interventional

Pilot Study of Raltegravir Lipodystrophy IISP

NCT01164605
View directory record Official record
Conditions
HIV Infection
Interventions
Raltegravir
Drug
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Phase 1 Interventional

Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV

NCT00842634
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
ZFN modified T cells, Structured Treatment Interruption
Biological · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
The Bronx, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 7, 2026, 12:41 AM EDT
Terminated Phase 2 Interventional Results available

Telephone Support to Improve Adherence to Anti-HIV Medications

NCT00988442
View directory record Official record
Conditions
HIV Infections
Interventions
Enhanced nursing telephone support, Standard care
Behavioral
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

NCT04147715
View directory record Official record
Conditions
Healthy Volunteer
Interventions
S-648414, Placebo, Midazolam, Dolutegravir
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Not applicable Interventional Results available

CSP #512 - Options in Management With Anti-Retrovirals

NCT00050089
View directory record Official record
Conditions
AIDS, HIV Infections
Interventions
No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP, Standard ART vs Mega ART
Other · Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
29
States / cities
Phoenix, Arizona • Long Beach, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Phase 3 Interventional

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

NCT00046176
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
abacavir/lamivudine, abacavir, lamivudine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
52
States / cities
Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Botswana TDF/FTC Oral HIV Prophylaxis Trial

NCT00448669
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg, Placebo Oral Tablet
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 39 Years
Enrollment
1,219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 7, 2026, 12:41 AM EDT
Not listed Phase 4 Interventional

Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain

NCT05463783
View directory record Official record
Conditions
HIV Infections, Obesity
Interventions
Biktarvy, Symtuza
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Not applicable Interventional

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

NCT00051831
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine, Enfuvirtide, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 7, 2026, 12:41 AM EDT
Recruiting Phase 4 Interventional

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

NCT07476339
View directory record Official record
Conditions
HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
Interventions
Bictegravir, emtricitabine, and tenofovir alafenamide
Drug
Lead sponsor
CAN Community Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients

NCT01422330
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
Etravirine
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Beverly Hills, California • North Hollywood, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 7, 2026, 12:41 AM EDT
Completed No phase listed Observational

Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy

NCT00326482
View directory record Official record
Conditions
Liver Fibrosis, Steatohepatitis, Elevated Transaminases
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Phase 1Phase 2 Interventional

ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects

NCT00004578
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Lamivudine, Stavudine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
10
States / cities
Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Phase 3 Interventional Results available

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)

NCT02429791
View directory record Official record
Conditions
HIV Infections
Interventions
DTG 50 mg, RPV 25 mg, CAR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
13
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Not applicable Interventional

Medications for Chronic HIV: Education and Collaboration

NCT01038076
View directory record Official record
Conditions
HIV Infections, Acquired Immunodeficiency Syndrome, Medication Adherence
Interventions
MedCHEC Tablet Computer & Adherence Care
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 7, 2026, 12:41 AM EDT
Terminated Phase 4 Interventional Results available

Kaletra and Viread in Antiretroviral Naïve Patients

NCT00679926
View directory record Official record
Conditions
HIV Infections
Interventions
Once daily
Drug
Lead sponsor
Oklahoma State University Center for Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 7, 2026, 12:41 AM EDT
Not listed Phase 2 Interventional

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

NCT00017992
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Emtricitabine, Stavudine
Drug
Lead sponsor
Triangle Pharmaceuticals
Industry
Eligibility
3 Months to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Phase 1 Interventional

The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children

NCT00000865
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 13 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Not applicable Interventional

Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs

NCT00050921
View directory record Official record
Conditions
HIV Infections
Interventions
somatropin, Hepatitis A virus, inactivated, Keyhole-Limpet Hemocyanin
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Not applicable Interventional

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

NCT00002392
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Phase 2 Interventional

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

NCT00000870
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Not applicable Interventional

Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy

NCT00109603
View directory record Official record
Conditions
HIV Infections, Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 7, 2026, 12:41 AM EDT
Completed Not applicable Interventional

The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens

NCT00152061
View directory record Official record
Conditions
HIV Infections
Interventions
3TC and FTC
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 7, 2026, 12:41 AM EDT
Completed No phase listed Observational Results available

Prospective Observational Epidemiologic Study of Maraviroc's Safety

NCT00665561
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Maraviroc along with an optimized background antiretroviral drug regimen, Optimized background antiretroviral drug regimen without maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
145
States / cities
Hobson City, Alabama • Huntsville, Alabama • Bakersfield, California + 87 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 7, 2026, 12:41 AM EDT